Cancer's Wall Breached: Paxalisib Unleashes Immune Fury on Resistant Breast Cancer!

Stunning Breakthrough: Kazia Therapeutics' (NASDAQ: KZIA) paxalisib shows transformative power against immunotherapy-resistant triple-negative breast cancer (TNBC).
Immune System Unleashed: Preclinical data reveals paxalisib reprograms the tumor microenvironment, supercharging the immune system's attack on cancer cells, especially when paired with checkpoint inhibitors^{6, 8}.
Hope in Human Trials: A new Phase 1b clinical trial, now dosing patients, aims to translate these groundbreaking findings into vital new treatments for advanced breast cancer^{4, 6}.

In a stunning revelation poised to reshape the fight against one of the most formidable cancers, Kazia Therapeutics today announced groundbreaking preclinical data for its lead drug, paxalisib. Published in the prestigious Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, the research unveils paxalisib's extraordinary potential to conquer immunotherapy resistance in triple-negative breast cancer (TNBC) – a notoriously aggressive and difficult-to-treat foe⁶.

Conducted by leading researchers at the renowned QIMR Berghofer Medical Research Institute, the study demonstrates how paxalisib, a potent PI3K/mTOR pathway inhibitor, can fundamentally rewire the battlefield within the tumor. It doesn't just fight cancer cells directly; it transforms the tumor microenvironment, paving the way for an invigorated immune assault by increasing the infiltration and activation of crucial CD4+ and CD8+ T cells^{6, 8}. When combined with immune checkpoint inhibitors like KEYTRUDA® (pembrolizumab), paxalisib ignited a powerful synergistic attack, leading to significant tumor regression and prolonged survival in preclinical models^{6, 8}.

"This landmark study offers a mechanistic and translational foundation for our newly launched Phase clinical trial of paxalisib in advanced breast cancer," declared Kazia's CEO. "It not only extends the therapeutic potential of paxalisib beyond brain cancers but also positions it at the forefront of innovative immunotherapy combinations in solid tumors."

This isn't just a scientific curiosity; it's a critical leap towards the clinic. Kazia has already dosed the first patient in a Phase 1b trial evaluating paxalisib with checkpoint inhibitors (such as pembrolizumab) or PARP inhibitors (like olaparib) in advanced breast cancer, marking a pivotal moment in the quest to turn these incredible preclinical successes into tangible hope for patients^{4, 6}. The publication, "Combination of the PI3K/mTOR inhibitor paxalisib with immune checkpoint inhibitors enhances antitumor activity in preclinical models of triple-negative breast cancer," is available online. For Kazia, these findings dramatically broaden paxalisib's horizons, previously focused on brain cancers like glioblastoma³, now targeting the urgent, unmet needs in aggressive solid tumors like TNBC.

Cancer's Wall Breached: Paxalisib Unleashes Immune Fury on Resistant Breast Cancer!

References

Stay Updated!